Page 34 - GTM-2-4
P. 34

Global Translational Medicine                                      The research advances in HPV integration




                    References  [58]  [57,94]  [95]  [96]   [97]     [73]  [75]  [86]  [98]  [76]  [77]   (Cont’d...)



                    Genes into which HPV integrates   at high frequency  FHIT, MYC  MACROD2, MIPOLA/TTC6,   TP63  LINC00392, LRP1B, DIAPH 2,  PROS1, LSP1P5, ANKRD26P1,  FHIT, MACROD2, ERBB2, RREB1  and more (24 hotspots identified)  N/A  BCL11B  Intergenic region of CHMP48 and   RALY‑AS1  BNC1, RSBN1, USP36, and   TAOK3  LINC00290, LINC02500, and   LENG9  N/A  NISCH, PBRM1  N/A













                    Number of integration   sites identified  N/A  (62 cases of cervical   cancer displayed HPV   integration)  308  1,002 in 24.8% of   non-cancer samples, 588   in 38.0% of precancer   samples, and 1597 in   69.0% of cancer samples  1  1  83  267  63  448 in CaSki and 60 in   clinical samples  74  4

                Table 1. Methods used to identify HPV integration sites across various cancers in studies published from 2020 onwards





                    Infected HPV   types  16, 18  16, 18, 31, 33,   39, 42, 45, 52,   56, 58, 59, 68,   70, 73, 82  6, 11, 16, 18,   31, 33, 34, 35,   39, 45, 52, 56,   58, 59, 66, 68,   69, 82, etc  51, 52, 59  70  16  16  16, 58  16, 35  18  18






                    Number of   samples  96  272  1,466  36  1       1    8     16   1    2      0 clinical   sample, HeLa   cell DNA used





                                  HPV double capture and Illumina   Tagmentation-assisted multiplex  PCR enrichment sequencing   HPV DNA hybridization capture  plus Illumina sequencing and  nanopore sequencing, FISH used to   visualize the integration site Nanopore sequencing and Illumina   HPV-enriched DNA for PacBio   multi-omics data on TCGA  Pooled CRISPR inverse PCR  sequencing (PCIP-seq), nanopore   microfluidics, PacBio sequencing,  nanopore sequencing and Illumina





                    Method (s) used  Dual-color FISH  sequencing  Virus capture sequencing  (TaME-seq2)  sequencing  sequencing with matched   Nanopore sequencing  Nanopore sequencing  sequencing  DNA enriched through   sequencing









                    Technology  FISH  2 nd -generation   sequencing  3 rd -generation   sequencing  3 rd -generation   sequencing combined   CRISPR  3 rd -generation   sequencing combined   with microfluidics








                    Cancer type  Cervical cancer






            Volume 2 Issue 4 (2023)                         8                        https://doi.org/10.36922/gtm.2034
   29   30   31   32   33   34   35   36   37   38   39